1
Home
Companies

Outlook Therapeutics

#9494

Rank

$50.56M

Marketcap

US United States

Country

Outlook Therapeutics
Leadership team

Mr. Ralph H. Thurman (Independent Exec. Chairman)

Mr. C. Russell Trenary III (Pres, CEO & Director)

Mr. Lawrence A. Kenyon CPA (Exec. VP, CFO, Treasurer, Company Sec. & Director)

Products/ Services
Biopharma, Biotechnology, Pharmaceutical, Therapeutics
Headquarters
Cranbury, New Jersey, United States
Established
2011
Company Registration
SEC CIK number: 0001649989
Traded as
OTLK
Social Media
URL
https://www.outlooktherapeutics.com
Overview
Location

Summary
History
Mission
Vision
Key Team
Recognition and Award
References
Summary
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.
History

Outlook was founded in late 2013 to focus on the development of innovative pharmaceuticals. The company has developed its portfolio of novel compounds targeting various indications and is actively engaging in collaborations with research partners, venture capitalists, and universities.

Mission
Our mission is to develop innovative treatments for chronic diseases that can improve patients’ lives.
Vision
Outlook strives to be a leader in the development of novel treatments to address unmet medical needs.
Key Team

Mr. Terry Dagnon (Chief Operations Officer)

Mr. Jeffrey Evanson (Chief Commercial Officer)

Rick Gregory (Director of Marketing & Communications)

Ms. Alicia Tozier (Sr. VP, Marketing & Market Access)

Mr. Joel Prieve (Sr. VP of Commercial Operations)

Dr. Balu N. Balasubramanian Ph.D. (Advisor)

Ms. Elizabeth A. Yamashita (Advisor)

Recognition and Awards
Outlook Therapeutics has been recognized with numerous awards, including the 2018 Stevie® Award for Innovation in Healthcare, the 2017 US Blockchain Association’s Blockchain Innovator of the Year award, and the 2018 Asia Biotech Award for leading research and development in drug discovery.
References

https://in.investing.com/equities/oncobiologics-inc

https://finance.yahoo.com/quote/OTLK/profile?p=OTLK

https://www.crunchbase.com/organization/oncobiologics

https://companiesmarketcap.com/

https://www.outlooktherapeutics.com

Dive deeper into fresh insights across Business, Industry Leaders and Influencers, Organizations, Education, and Investors for a comprehensive view.

Outlook Therapeutics
Leadership team

Mr. Ralph H. Thurman (Independent Exec. Chairman)

Mr. C. Russell Trenary III (Pres, CEO & Director)

Mr. Lawrence A. Kenyon CPA (Exec. VP, CFO, Treasurer, Company Sec. & Director)

Products/ Services
Biopharma, Biotechnology, Pharmaceutical, Therapeutics
Headquarters
Cranbury, New Jersey, United States
Established
2011
Company Registration
SEC CIK number: 0001649989
Traded as
OTLK
Social Media
URL
https://www.outlooktherapeutics.com